Epic Sciences tests for longevity, not just biology. Our groundbreaking, unbiased approach, Functional Cell Profiling (FCP) liquid biopsy platform, sees those rare cells that others miss. By peering more deeply into the single cell, we can perceive both genotype and phenotypes together, uncovering the heterogeneity and delivering tests that are personalized, predictive and proven. We give cancer patients and their physicians the clear, accurate insights they need to choose the best course of therapy, in days rather than weeks or months.
Essential to detecting and understanding cancer heterogeneity, Epic Sciences' groundbreaking circulating tumor cell (CTC) detection engine, FCP, analyzes all nucleated cells within a blood sample at single cell resolution. Our platform also allows us to characterize immune cell subsets which has great potential in predicting response in immunomodulators.learn more
The AR-V7 test is the first and only Medicare reimbursed, clinically-validated, predictive circulating tumor cell (CTC) liquid biopsy test for metastatic castration-resistant prostate cancer (mCRPC). Requiring only a simple, non-invasive blood draw, this groundbreaking test empowers patients, with their doctors, the confidence to choose the most effective precision therapies.
For pharmaceutical and clinical investigation partners, our Decision Point program delivers a bias-free approach for cancer research, to develop clinical solutions that accelerate drug development and provide valuable insights into the dynamics of cancer growth, evolution and heterogeneity.
single CTC genomes sequenced
patient samples contracted
Of the roughly 50 million cells in a typical blood sample, about 5 are cancer cells on their way to form tumors elsewhere in the body. Modern cancer diagnostics can’t see them, but we can.